Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site

摘要: Cancer may be diagnosed in advanced stages, when the patient has already developed metastasis, with symptoms that can also observed benign diseases. The objective of this study was to evaluate tumor marker sensitivity and specificity differential diagnosis patients suspected signs cancer. We studied 2.711 consecutive admitted Internal Medicine Department our hospital cancer; 1.240 had non-malignant processes 1.471 malignant disease. Determinations were considered positive for malignancy serum levels carcinoembryonic antigen >15 ng/ml (>20 renal failure or liver disease), alpha fetoprotein >40 (>80 diseases), carbohydrate (CA) 19.9 > 200 U/ml (>500 diseases gamma glutamyl transpeptidase (GGT) 1.000 jaundice GGT 150 UI/L), neuron-specific enolase >45 (renal >50 ng/ml; samples hemolysis excluded), prostate-specific 30 (excluding acute prostatitis), tumor-associated glycoprotein-72 >80 U/ml, cytokeratin 19 fragment 21-1 7.5 (>19 failure; >11 cirrhosis jaundice), >3.5 squamous cell carcinoma skin disorders), CA 15.3 >100 125 >350 (>600 pleural effusion >900 those ascites). There a 97.6% without malignancy, 67.4% 75.4% 1,280 epithelial tumors (53.7% locally 79.4% metastases). Sensitivity 81.4% cancer unknown primary site. Tumor markers useful between non-epithelial tumors, brain masses (metastases vs. tumors), origin different clinical situations such as wasting syndrome, effusions, bone lesions, effusions predictive value higher than 95%. are an aid evaluation risk these reduce hospitalization time, morbidity, number diagnostic tests required diagnosis.